The simultaneous targeting of ferroptosis and the tumor microenvironment through drug delivery/nanomedicine or biomaterials is feasible, but it is not included in our scope.[172, 173, 174, 175] Here, we aim to explore the feasibility of directly modulating both PD-L1 and tumor cell ferroptosis through small molecules or key proteins (e.g., transcription factors and epigenetic modulators), particularly in the context of breast cancer. The gene discussed is CD274; the disease is breast cancer.